Home > Press > NanoKTN Helps UK Start-Up Reach International Audience and Profitability
Abstract:
The NanoKTN is pleased to announce that one of its members, NanoSight, has recently secured its 250th sale and has reached profitability for the first time since the company was established in 2005. NanoSight's CEO Jeremy Warren believes support from the NanoKTN has had significant, commercial impact on the success of the business.
NanoSight's technology has been installed worldwide with users including BASF, GlaxoSmithKline, Merck, Novartis, Pfizer, Proctor and Gamble, Roche and Unilever, together with many leading universities and research institutes.
UK-based NanoSight has developed a revolutionary technique to view nanoparticles down to the size of several millionths of a millimetre. This opens previously unimagined possibilities such as for the development of viral vaccines and drug delivery systems, both of which require a great deal of precision. The NanoSight technique measures on a particle-by-particle basis and so generates high-resolution particle-size distributions, allowing an accurate and precise measurement of virus or drug delivery particle numbers and sizes. This has clear implications for the manufacturing processes as well as helping to optimize the product yield.
From their start, NanoSight has attended NanoKTN events as both a speaker and exhibitor, using them as a means of securing business contacts within industry and academia. By talking to industry professionals within the field and by meeting with academics from leading research institutions and universities, NanoSight has been able to increase its new business prospects as well as providing the company with a platform to deliver information about the benefits of its technology directly to its target audience.
"There is no doubt that the NanoKTN events have been invaluable to our business, as has the dedicated commitment and support which has been provided to us by the NanoKTN staff," explains Warren. "They have provided us with vital access to the nanotechnology market, both in the UK and abroad, helping us to develop our market understanding. Through conferences and focus groups, the NanoKTN has made the market more coherent, bringing academia and commercial players together, developing a solid MNT network."
With continued support from the NanoKTN's Theme Managers, NanoSight has been able to develop contact with key market professionals and generate new sales internationally. NanoSight has grown rapidly and has secured its position in the market as a leading manufacturer of unique nanoparticle characterization technology, more than 90% of sales being outside the UK.
CEO Warren adds, "I would strongly recommend companies joining the NanoKTN. Membership is essential to those wanting to learn more about the key players in the nanotechnology market and to help to build their company profile. Their events have provided us with valuable networking opportunities and are crucially important to ensure the growth of the UK nanotechnology market."
####
For more information, please click here
Contacts:
General KTN enquiries
T: +44 (0)1740 625 790
Copyright © NanoKTN
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Tools
Turning up the signal November 8th, 2024
Quantum researchers cause controlled ‘wobble’ in the nucleus of a single atom September 13th, 2024
Faster than one pixel at a time – new imaging method for neutral atomic beam microscopes developed by Swansea researchers August 16th, 2024
Financial Reports
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Nanobiotechnology
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
The mechanism of a novel circular RNA circZFR that promotes colorectal cancer progression July 5th, 2024
New-Contracts/Sales/Customers
Bruker Light-Sheet Microscopes at Major Comprehensive Cancer Center: New Advanced Imaging Center Powered by Two MuVi and LCS SPIM Microscopes March 25th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
Veeco Announces Aledia Order of 300mm MOCVD Equipment for microLED Displays: Propel™ Platform First 300mm System with EFEM Designed for Advanced Display Applications October 20th, 2020
GREENWAVES TECHNOLOGIES Announces Next Generation GAP9 Hearables Platform Using GLOBALFOUNDRIES 22FDX Solution October 16th, 2020
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||